Show simple item record

dc.contributor.authorDing, Yunpengen_US
dc.contributor.authorPedersen, Eva Ringdalen_US
dc.contributor.authorJohansson, Stefanen_US
dc.contributor.authorGregory III, Jesse F.en_US
dc.contributor.authorUeland, Per Magneen_US
dc.contributor.authorSvingen, Gard Frodahl Tveitevågen_US
dc.contributor.authorHelgeland, Øyvinden_US
dc.contributor.authorMeyer, Klausen_US
dc.contributor.authorFredriksen, Åseen_US
dc.contributor.authorNygård, Ottaren_US
dc.PublishedNMCD. Nutrition Metabolism and Cardiovascular Diseases 2016, 26(6):495-501eng
dc.description.abstractBackground: Methylenetetrahydrofolate dehydrogenase (MTHFD1) catalyzes three sequential reactions that metabolize derivatives of tetrahydrofolate (THF) in folate-dependent one-carbon metabolism. Impaired MTHFD1 flux has been linked to disturbed lipid metabolism and oxidative stress. However, limited information is available on its relation to the development of atherothrombotic cardiovascular disease. Methods and results: We explored the association between a MTHFD1 polymorphism (rs1076991 C > T ) and acute myocardial infarction (AMI), and potential effect modifications by folic acid/B12 and/or vitamin B6 treatment in suspected stable angina pectoris patients (n Z 2381) participating in the randomized Western Norway B Vitamin Intervention Trial (WENBIT). During the median follow-up of 4.9 years 204 participants (8.6%) suffered an AMI. After adjusting for established CVD risk factors, the MTHFD1 polymorphism was significantly associated with AMI (HR: 1.49; 95% CI, 1.23e1.81). A similar association was observed among patients allocated to treatment with vitamin B6 alone (HR: 1.53; 95% CI, 1.01e2.31), and an even stronger relationship was seen in patients treated with both vitamin B6 and folic acid/B12 (HR: 2.35; 95% CI, 1.55 e3.57). However, no risk association between the MTHFD1 polymorphism and AMI was seen in patients treated with placebo (HR: 1.29; 95% CI, 0.86e1.93) or folic acid/B12 (1.17; 95% CI, 0.83e1.65). Conclusion: A common and functional MTHFD1 polymorphism is associated with increased risk of AMI, although the risk seems to be dependent on specific B vitamin treatment. Further studies are warranted to elucidate the possible mechanisms, also in order to explore potential effect modifications by nutritional factors.en_US
dc.relation.ispartof<a href="" target="blank">MTHFD1 and relevant biomarkers in cardiovascular disease: Observational studies in patients with suspected stable angina pectoris in Norway</a>
dc.rightsAttribution CC BY-NC-NDeng
dc.subjectMyocardial infarctioneng
dc.subjectOne carbon metabolismeng
dc.subjectB vitamineng
dc.titleB vitamin treatments modify the risk of myocardial infarction associated with a MTHFD1 polymorphism in patients with stable angina pectorisen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2015 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY-NC-ND
Except where otherwise noted, this item's license is described as Attribution CC BY-NC-ND